Skip to main content
. Author manuscript; available in PMC: 2014 Apr 10.
Published in final edited form as: J Nucl Med. 2012 Aug 23;53(10):1592–1600. doi: 10.2967/jnumed.111.102293

FIGURE 3.

FIGURE 3

Comparison of Tumor (%ID/g):Muscle (%ID/g) Ratios (T:M) of 89Zr-df-Onartuzumab in MKN-45 and U87-MG xenografts from 18 h to 5 d. Bars represent mean T:M ± SD (n= 4). Bars at 3 d include T:M from 89Zr-df-Onartuzumab competitive blocking study in MKN-45 xenografts injected with 89Zr-df-Onartuzumab only or 89Zr-df-Onartuzumab + 10 nmoles Onartuzumab.